CA2599329A1 - Pharmaceutical composition - Google Patents

Pharmaceutical composition Download PDF

Info

Publication number
CA2599329A1
CA2599329A1 CA002599329A CA2599329A CA2599329A1 CA 2599329 A1 CA2599329 A1 CA 2599329A1 CA 002599329 A CA002599329 A CA 002599329A CA 2599329 A CA2599329 A CA 2599329A CA 2599329 A1 CA2599329 A1 CA 2599329A1
Authority
CA
Canada
Prior art keywords
composition according
rna
microparticle composition
microparticle
ova
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002599329A
Other languages
English (en)
French (fr)
Inventor
James Edward Eyles
Angela Westwood
Stephen J. Elvin
Gareth David Healey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UK Secretary of State for Defence
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0504276A external-priority patent/GB0504276D0/en
Priority claimed from GB0511801A external-priority patent/GB0511801D0/en
Application filed by Individual filed Critical Individual
Publication of CA2599329A1 publication Critical patent/CA2599329A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/07—Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002599329A 2005-03-02 2006-03-02 Pharmaceutical composition Abandoned CA2599329A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0504276A GB0504276D0 (en) 2005-03-02 2005-03-02 Pharmaceutical composition
GB0511801.3 2005-03-02
GB0511801A GB0511801D0 (en) 2005-06-10 2005-06-10 Pharmaceutical composition
GB0504276.7 2005-06-10
PCT/GB2006/000751 WO2006092607A1 (en) 2005-03-02 2006-03-02 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
CA2599329A1 true CA2599329A1 (en) 2006-09-08

Family

ID=36353665

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002599329A Abandoned CA2599329A1 (en) 2005-03-02 2006-03-02 Pharmaceutical composition

Country Status (8)

Country Link
US (1) US20080138431A1 (cg-RX-API-DMAC7.html)
EP (1) EP1853227B1 (cg-RX-API-DMAC7.html)
JP (1) JP2008531672A (cg-RX-API-DMAC7.html)
AT (1) ATE438385T1 (cg-RX-API-DMAC7.html)
AU (1) AU2006219717B2 (cg-RX-API-DMAC7.html)
CA (1) CA2599329A1 (cg-RX-API-DMAC7.html)
DE (1) DE602006008278D1 (cg-RX-API-DMAC7.html)
WO (1) WO2006092607A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ535952A (en) 2002-04-04 2009-01-31 Coley Pharm Gmbh Immunostimulatory G,U-containing oligoribonucleotides
WO2007062107A2 (en) 2005-11-25 2007-05-31 Coley Pharmaceutical Gmbh Immunostimulatory oligoribonucleotides
EP2288381A2 (en) * 2008-05-02 2011-03-02 Cancer Research Technology Limited Products and methods for stimulating an immune response
US9770463B2 (en) 2010-07-06 2017-09-26 Glaxosmithkline Biologicals Sa Delivery of RNA to different cell types
PT3243526T (pt) 2010-07-06 2020-03-04 Glaxosmithkline Biologicals Sa Distribuição de arn para despoletar múltiplas vias imunitárias
US10487332B2 (en) 2010-07-06 2019-11-26 Glaxosmithkline Biologicals Sa Immunisation of large mammals with low doses of RNA
CN103153284B (zh) 2010-07-06 2015-11-25 诺华股份有限公司 含有其pKa值有利于RNA递送的脂质的脂质体
FI4005592T3 (fi) 2010-07-06 2023-01-13 Virionin kaltaisia kuljetuspartikkeleita itsereplikoituville rna-molekyyleille
JP5911870B2 (ja) 2010-08-31 2016-04-27 ノバルティス アーゲー 免疫原をコードするrnaの送達のためのpeg化リポソーム
KR102266691B1 (ko) 2010-10-11 2021-06-23 노파르티스 아게 항원 전달 플랫폼
JP2014522842A (ja) 2011-07-06 2014-09-08 ノバルティス アーゲー 免疫原性組み合わせ組成物およびその使用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR012448A1 (es) * 1997-04-18 2000-10-18 Ipsen Pharma Biotech Composicion en forma de microcapsulas o de implantes que comprende un excipiente biodegradable, polimero o co-polimero, o una mezcla de talesexcipientes, y una sustancia activa o una mezcla de sustancias activas, procedimiento para la preparacion de una sustancia soluble en agua de elevada
NZ532274A (en) * 2001-10-03 2006-02-24 Chiron Corp Adjuvanted meningococcus compositions
SI1589934T1 (sl) * 2003-01-06 2016-02-29 Corixa Corporation Corporation Service Company Določene aminoalkil glukozaminid fosfat spojine in njih uporaba
JP2006522806A (ja) * 2003-03-26 2006-10-05 マルチセル・イミュノセラピューティクス,インコーポレイテッド 細胞死及び/又はアポトーシスを誘導するための、選択されたrnaモチーフ

Also Published As

Publication number Publication date
DE602006008278D1 (de) 2009-09-17
WO2006092607A1 (en) 2006-09-08
ATE438385T1 (de) 2009-08-15
US20080138431A1 (en) 2008-06-12
JP2008531672A (ja) 2008-08-14
EP1853227A1 (en) 2007-11-14
AU2006219717B2 (en) 2009-05-21
AU2006219717A1 (en) 2006-09-08
EP1853227B1 (en) 2009-08-05

Similar Documents

Publication Publication Date Title
JP6320912B2 (ja) 浸透圧媒介性放出合成ナノ担体
Schlosser et al. TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses
Joshi et al. Biodegradable particles as vaccine delivery systems: size matters
Joshi et al. Biodegradable particles as vaccine antigen delivery systems for stimulating cellular immune responses
Singh et al. Charged polylactide co-glycolide microparticles as antigen delivery systems
EA030863B1 (ru) Композиции для усиления иммунного ответа на антиген, содержащие синтетические наноносители, и их применения
Zhang et al. Potent antigen-specific immune responses stimulated by codelivery of CpG ODN and antigens in degradable microparticles
Zhang et al. A comparative study of the antigen‐specific immune response induced by co‐delivery of CpG ODN and antigen using fusion molecules or biodegradable microparticles
Goforth et al. Immune stimulatory antigen loaded particles combined with depletion of regulatory T-cells induce potent tumor specific immunity in a mouse model of melanoma
Liu et al. Encapsulation of Poly I: C and the natural phosphodiester CpG ODN enhanced the efficacy of a hyaluronic acid-modified cationic lipid-PLGA hybrid nanoparticle vaccine in TC-1-grafted tumors
CN108324938B (zh) 一种颗粒型佐剂及其制备方法和应用
Joshi et al. Characterizing the antitumor response in mice treated with antigen-loaded polyanhydride microparticles
CN114404580A (zh) 一种树突状细胞癌症疫苗及其应用
AU2006219717B2 (en) Pharmaceutical composition
Kumar et al. Development of soluble inulin microparticles as a potent and safe vaccine adjuvant and delivery system
WO2023201786A1 (zh) 一种免疫佐剂组合物和基于该组合物的癌症疫苗及其应用
JP2005514326A (ja) ミクロスフェア中に封入されたタンパク質およびアジュバントを送達するための組成物および方法
AU2003219805A1 (en) Electroporation methods for introducing bioactive agents into cells
Perrie et al. Recent developments in particulate-based vaccines
WO2023201787A1 (zh) 一种基于癌症特异性t细胞的细胞系统、淋巴细胞药物及其应用
JP2008531672A5 (cg-RX-API-DMAC7.html)
WO2005023293A1 (en) Vaccine composition comprising il-12 adjuvant encapsulated in controlled-release microsphere
Thiele et al. Phagocytosis of synthetic particulate vaccine delivery systems to program dendritic cells
Chadhar et al. A Review on Novel Delivery Vehicles for Vaccines Development
Patel et al. Cationic nanoparticles for delivery of CpG oligodeoxynucleotide and ovalbumin: In vitro and in vivo assessment

Legal Events

Date Code Title Description
FZDE Discontinued